Oncoproteomic approaches to cancer marker discovery: The case of colorectal cancer

Biomarkers in Disease: Methods, Discoveries and Applications: Biomarkers in Cancer

Volumn , Issue , 2015, Pages 53-71

  Salvatore, Francesco ^a,b,c   Corbo, Claudia ^a   Gemei, Marica ^a   Vecchio, Luigi Del ^a,b  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS SDN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; CLINICAL RESEARCH; DIAGNOSIS; ELECTROPHORESIS; MASS SPECTROMETRY; PATIENT TREATMENT; POLYACRYLATES; PROTEINS;

CELLULAR BEHAVIORS; COLORECTAL CANCERS (CRC); MATRIX-ASSISTED LASER DESORPTION-IONIZATION TIME-OF-FLIGHT MASS; PERSONALIZED THERAPIES; PROTEOMIC APPROACHES; PROTEOMIC BIOMARKERS; PROTEOMIC TECHNIQUES; TWO-DIMENSIONAL GEL ELECTROPHORESIS;

DISEASES;

EID: 84943389387     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-7681-4_16     Document Type: Chapter

References (37)

1. Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis. 1998;19:1853-61.
2. Anderson NL, Anderson NG, Pearson TW, Borchers CH, Paulovich AG, Patterson SD, et al. A human proteome detection and quantitation project. Mol Cell Proteomics. 2009;8:883-6.
3. Biomarkers in cancer: an introductory guide for advocates. Research advocacy network. 2010. http://researchadvocacy.org/images/uploads/downloads/BiomarkerinCancer_WebDownloadVersion.pdf. Retrieved 26 Apr 2013.
4. Chan D, Lee SC. Serial changes in expression of proteins in response to neoadjuvant chemotherapy in breast cancer. In: Yahwardiah S, editor. Oncogene and cancer - from bench to clinic. InTech; 2013. p. 3-38.
5. Cho WC, Cheng CH. Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics. 2007;4(3):401-10.
6. Corbo C, Orrú S, Gemei M, Noto RD, et al. Protein cross-talk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity. Proteomics. 2012;12(12):2045-59.
7. Corbo C, Orrú S, Salvatore F. SRp20: an overview of its role in human diseases. Biochem Biophys Res Commun. 2013;436(1):1-5.
8. de Wit M, Jimenez CR, Carvalho B, et al. Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut. 2012;61(6):855-64.
9. Engholm-Keller K, Larsen MR. Technologies and challenges in large-scale phosphoproteomics. Proteomics. 2013;13(6):910-31.
10. Engwegen J.Y.M.N, Gast M.C.W, Schellens J.H.M, Beijnen J.H. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006;27(5):2517-259.
11. Ettarh R. Colorectal cancer: it starts and it runs. In: Ettarh R, editor. Colorectal cancer biology - from genes to tumor. 2012. p. 1-8. http://www.intechopen.com/books/colorectal-cancer-biol ogy-from-genes-to-tumor/colorectal-cancer-it-startsand-it-runs.
12. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-67.
13. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature. 1985;314:53-7.
14. Gala M, Chung DC. Hereditary colon cancer syndromes. Semin Oncol. 2011;38(4):490-9.
15. Gemei M, Mirabelli P, Di Noto R, et al. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer. 2013;119(4):729-38.
16. Guerrier L, Thulasiraman V, Castagna A, et al. Reducing protein concentration range of biological samples using solid-phase ligand libraries. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;833(1):33-40.
17. Hakomori S. Tumor-associated glycolipid antigens, their metabolism and organization. Chem Phys Lipids. 1986;42:209-33.
18. Han DK, Eng J, Zhou H, Aebersold R. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat. Biotechnol. 2001;19:946-51
19. Jimenez CR, Knola JC, Meijerb GA, Fijnemanb RJA. Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics. 2010;73:1873-95.
20. Lowe JB. Glycosylation, immunity, and autoimmunity. Cell. 2001;104(6):809-12.
21. Moorhead GB, De Wever V, Templeton G, Kerk D. Evolution of protein phosphatases in plants and animals. Biochem J. 2009;417:401-9.
22. Neilson KA, Ali NA, Muralidharan S, Mirzaei M, Mariani M, Assadourian G, Lee A, van Sluyter SC, Haynes PA. Less label, more free: approaches in label-free quantitative mass spectrometry. Proteomics. 2011;11(4):535-53.
23. Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis. 2012;14(1):3-17.
24. O’Farell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975;250:4007-21.
25. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, and Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell Proteomics. 2002;1(5):376-386.
26. Pastor MD, Nogal A, Molina-Pinelo S, Paz-Ares L, Carnero A. Oncoproteomic approaches in lung cancer research. In: López-Camarillo C, Aréchaga-Ocampo E, editors. Oncogenomics and cancer proteomics - novel approaches in biomarkers discovery and therapeutic targets in cancer. 2013. Chapter 7. http://www.intechopen.com/books/oncogenomics-and-cancer-proteomics- novel-approaches-in-biomarkers-discovery-and-therapeutic-targets-in-cancer/oncoproteomic- approaches-in-lung-cancer-research.
27. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971-83.
28. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using aminereactive isobaric tagging reagents. Molecular and Cellular Proteomics. 2004;3:1154-1169.
29. Schmidt SR, Schweikart F, Andersson ME. Current methods for phosphoprotein isolation and enrichment. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;849(1-2):154-62.
30. Sefton BM, Shenolikar S. Overview of protein phosphorylation. Curr Protoc Mol Biol. 2001;11:3-4, Chapter 18 (Unit 18).
31. Tanaka T, Tanaka M, Takahiro T, Ishigamori R. Biomarkers for colorectal cancer. Int J Mol Sci. 2010;11:3209-25.
32. Tumor markers fact sheet. American Cancer Society 2013. www.cancer.org/tumor-markers-pdf
33. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis. 1997;18:2071-7.
34. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res. 2007;96:23-50.
35. Van Houdt WJ, Emmink BL, Pham TV, et al. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics. 2011;10(12):M111.011353.
36. Varki A. Glycosylation changes in cancer. In: Varki A, Cummings R, Esko J, et al., editors. Essentials of glycobiology. 1999. Chapter. http://www.ncbi.nlm.nih.gov/books/NBK20710/.
37. Zhang B, VerBerkmoes NC, Langston MA, et al. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res. 2006;5(11):2909-18.